AI 热点

Isomorphic Labs 完成 50 亿美元 C 轮融资,推进 AI 药物设计

Unite.AI更新于 11月17日 21:34

Isomorphic Labs Raises $5B Series C to Advance AI Drug Design

AI 导读

Isomorphic Labs 于 2026 年 11 月 17 日宣布完成 50 亿美元 C 轮融资,由 Greenoaks 和 Sequoia Capital 联合领投。资金将用于继续开发其自研药物设计引擎 IsoDDE、拓展新的生物学领域并建设全球 AI 生物工程基础设施,同时搭建转化与临床开发能力,推动候选药物进入临床试验。此前公司于 2026 年 5 月完成由 Thrive Capital 领投的 21 亿美元 B 轮,2025 年 3 月完成 6 亿美元首轮外部融资。

推荐理由

AI 评分 63

融资规模与历轮节奏并列,可看出 AI 制药从模型研发走向临床基础设施的资源投向。

主题

标签

正文

Isomorphic Labs announced on November 17, 2026 that it had raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital, giving the AI drug-discovery company new capital to expand its design engine and move therapeutic candidates toward clinical trials.

Proceeds will fund further development of IsoDDE, the company’s proprietary drug-design engine, expansion into new areas of biology, and global infrastructure for AI-led bioengineering. Isomorphic is also creating a partner ecosystem to study the mechanisms that drive disease. The company will also build translational and clinical-development infrastructure to move research toward patient testing and support candidates approaching trials.

Founder and CEO Demis Hassabis described the intended effect in the funding release: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

The new financing follows a $2.1 billion Series B announced on May 12, 2026, led by Thrive Capital. Alphabet and GV participated in that round alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Thrive also led the $600 million first external round announced on March 31, 2025, which included GV and follow-on capital from Alphabet.

At the center of the business is IsoDDE, which the company describes as a collection of AI simulation models built to handle different therapeutic areas and types of drugs. The system searches chemical space to design and refine molecules with drug-like properties, while proprietary agents navigate and reason through complex biology.

Isomorphic reports positive preclinical outcomes from wholly owned oncology and immunology programs and from partnered work, providing the basis for its planned move toward clinical trials.

Beyond its wholly owned programs, Isomorphic’s partnership portfolio includes Novartis, Eli Lilly and Johnson & Johnson. The Eli Lilly collaboration focuses on small-molecule therapeutics against undisclosed targets, while the multi-target Johnson & Johnson collaboration spans small molecules and biologics.

Novartis began working with Isomorphic in January 2024 on small molecules against three challenging targets. The companies expanded that work in February 2025, adding up to three additional research programs. Together, these programs give Isomorphic a portfolio that pairs company-owned oncology and immunology work with partnered research spanning different drug modalities.

The Series C gives Isomorphic the resources to develop its models and clinical-development infrastructure together. The central test is whether the reported preclinical progress translates into clinical evidence as candidates from its owned and partnered programs enter human trials.

来源

Unite.AI